All In Biotech

Free tool

FAERS Monitor: Iyuzeh

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216472 or its brand name (Iyuzeh, Latanoprost). Reports on generic versions are filed under their own applications.

Reports

638

Serious

80

13% of reports

Hospitalization

11

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye irritation153
  • eye pain87
  • vision blurred61
  • ocular hyperaemia57
  • intraocular pressure increased55
  • drug ineffective39
  • product quality issue39
  • dry eye33
  • eye pruritus32
  • foreign body sensation in eyes31
  • lacrimation increased27
  • headache24
  • visual impairment23
  • photophobia22
  • condition aggravated19

Reports by year received

View as table
YearReports
201216
201329
201427
201551
201661
2017134
201848
201971
202070
202131
20231
202423
202546
202630

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,521 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
foreign body sensation in eyesSignal31161.1114.24,752
intraocular pressure increasedSignal55142.5110.67,558
eye irritationSignal15387.976.513,053
eye painSignal8750.941.94,212
ocular hyperaemiaSignal5739.630.92,111
photophobiaSignal2238.625.6768
eye pruritusSignal3231.422.4913
lacrimation increasedSignal2729.520.4715
dry eyeSignal3321.815.6636
vision blurredSignal6114.711.5767
product quality issueSignal399.57.0289
visual impairmentSignal236.14.194
condition aggravatedSignal192.11.39
headache241.30.91
drug ineffective391.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.